Skip to main content

Bosentan

ADVERTISEMENT
Identification
Molecular formula
C27H29N5O6S
CAS number
147536-97-8
IUPAC name
N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide
State
State

At room temperature, Bosentan is in a solid state.

Melting point (Celsius)
111.00
Melting point (Kelvin)
384.15
Boiling point (Celsius)
553.40
Boiling point (Kelvin)
826.55
General information
Molecular weight
551.63g/mol
Molar mass
551.6290g/mol
Density
1.4260g/cm3
Appearence

Bosentan is usually found as a white to off-white crystalline powder.

Comment on solubility

Solubility of N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide

The solubility of N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide in various solvents can be a critical factor in its application. Here are some key points to consider regarding its solubility:

  • Polar Solvents: The presence of polar functional groups suggests that this compound may exhibit moderate solubility in polar solvents such as water and methanol.
  • Non-Polar Solvents: Conversely, given its hydrophobic cyclohexyl group, solubility in non-polar solvents like hexane may be less favorable.
  • Temperature Influence: It is also essential to note that solubility tends to increase with temperature, implying that heating may enhance the dissolution of this compound in certain solvents.
  • pH Dependence: The acidic and basic properties of the compound, influenced by the carboxamide and sulfamide groups, can lead to varied solubility based on the pH of the solution.

Overall, understanding the solubility profile of this chemical compound is essential for its effective use in pharmaceuticals or related fields. The careful selection of solvents based on the factors outlined above can optimize its solubility and, consequently, its efficacy in various applications.

Interesting facts

Interesting Facts about N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide

N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide, often referred to in shorthand as a medicinal compound, presents a fascinating realm of study in the field of medicinal chemistry. Here are some notable aspects:

  • Dual Mechanism: This compound features a unique combination of functional groups, enabling it to have dual mechanisms of action. Such compounds have the potential to target multiple biological pathways, which is particularly advantageous in treating complex diseases.
  • Structural Insight: The structural configuration, with a pyridine ring conjugated with various moieties, provides insights into how molecule orientation can affect its biological efficacy. Pyridine derivatives are known for their role as building blocks in drug design.
  • Therapeutic Applications: This compound is being investigated for its potential use in therapies targeting various conditions, due to its impressive interactions with biological systems. Researchers are particularly intrigued by its possible role in oncology and anti-inflammatory treatments.
  • Combination Approaches: The incorporation of a sulfamoyl group in its structure suggests that this compound could yield synergy when combined with other therapies, enhancing overall treatment outcomes.
  • Research and Development: Ongoing research aims to understand the pharmacodynamics and pharmacokinetics of this compound, shedding light on its therapeutic window and optimizing its utility in clinical settings.

In summary, N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide stands at the frontier of modern chemistry, showcasing the intricate relationship between structure and activity in drug discovery. As scientists continue to unravel its complexities, it holds promise for significant advancements in therapeutic strategies.

Synonyms
29094-66-4
N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpicolinamide
N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyridine-2-carboxamide
DB-221285